Roche invests 430 million Swiss francs at sites in Germany and Switzerland

RocheRoche has approved extensive investment plans for its Penzberg, Mannheim and Kaiseraugst sites. Around 280 million Swiss francs will be invested in expanding biotech drug research and development activities at Penzberg. This decision will ensure that the company's own value added chain is exploited to its full potential in the development and production of biopharmaceuticals mainly for oncology applications.

A total of some 150 million francs will be invested at Mannheim and Kaiseraugst in expanding modern syringe filling capacities for drugs such as Mircera, Pegasys or Actemra.

Commenting on the decision, Roche CEO and Chairman of the Board of Directors, Franz B. Humer, said: "After conducting a thorough evaluation of our production sites in many regions of the world and taking on board local business conditions at each, we have decided to make investments at these three sites in Germany and Switzerland. With our biopharmaceuticals heavily in demand, this step will both safeguard and expand production. Investments like this are very much long term in nature and they create hundreds of jobs in and around the company. It is therefore essential that a stable, industry-friendly environment be maintained in the long term."

The decision means that Roche’s investment in Pharma production equipment in the last five years has totalled around 1 billion Swiss francs (about 600 million euros) each in Germany and in Switzerland, resulting in the creation of several hundred new jobs.

The Roche Group - a pioneer in the biotechnology sector
Roche has invested in biotechnology from the outset, identifying important trends and technologies as they have emerged. Research has been pursued in the key areas of genetics, genomics and proteomics, and cutting-edge technologies – monoclonal antibodies, PCR and molecular genetic tests - have been developed to permit the broad application of biotechnology in medicine.

The Roche Group is now a leading supplier of biotechnology-based products for physicians and patients. Medicines and tests taking the patient's individual genetic characteristics into account are already available today.

Today, five of the Group's top ten pharmaceuticals are products of biotechnological research; they account for around 45 per cent of the Pharma Division's total sales. Measured by sales and production capacities of biopharmaceuticals, the Roche Group is the world's leading biotech company.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders and diseases of the central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invests approximately 7 billion Swiss francs a year in R&D. Worldwide, the Group employs about 75,000 people. For further information please visit www.roche.com.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...